Efficacy and safety results of a randomized, double-blind, vehicle-controlled phase 2 study of roflumilast foam 0.3% in patients with seborrheic dermatitis

被引：0
|
作者：
Zirwas, M. [1 ,2 ]
机构：
[1] Prob Med Res, Dermatologists Cent States, Bexley, OH USA
[2] Ohio Univ, Bexley, OH USA
[3] Arcutis Biotherapeut Inc, Westlake Village, CA USA
来源：
EXPERIMENTAL DERMATOLOGY | 2021年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
26
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a randomized, double-blind, vehicle-controlled phase 2 study
    Zirwas, Matthew
    Draelos, Zoe D.
    DuBois, Janet
    Kircik, Leon
    Moore, Angela
    Gold, Linda Stein
    Higham, Robert C.
    Navale, Lynn
    Burnett, Patrick
    Berk, David R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB47 - AB47
  • [2] Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial
    Zirwas, Matthew J.
    Draelos, Zoe D.
    DuBois, Janet
    Kircik, Leon H.
    Moore, Angela Y.
    Gold, Linda Stein
    Alonso-Llamazares, Javier
    Bukhalo, Michael
    Bruce, Suzanne
    Eads, Kimmie
    Green, Lawrence J.
    Guenthner, Scott T.
    Ferris, Laura K.
    Forman, Seth B.
    Kempers, Steven E.
    Lain, Edward
    Lynde, Charles W.
    Pariser, David M.
    Toth, Darryl P.
    Yamauchi, Paul S.
    Higham, Robert C.
    Krupa, David
    Burnett, Patrick
    Berk, David R.
    JAMA DERMATOLOGY, 2023, 159 (06) : 613 - 620
  • [3] Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
    Blauvelt, Andrew
    Draelos, Zoe D.
    Gold, Linda Stein
    Alonso-Llamazares, Javier
    Bhatia, Neal
    DuBois, Janet
    Forman, Seth B.
    Gooderham, Melinda
    Green, Lawrence
    Guenthner, Scott T.
    Hebert, Adelaide A.
    Lain, Edward
    Moore, Angela Y.
    Papp, Kim A.
    Zirwas, Matthew
    Kato, Saori
    Snyder, Scott
    Krupa, David
    Burnett, Patrick
    Berk, David R.
    Chu, David H.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (05) : 986 - 993
  • [4] Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study
    Kircik, Leon H.
    Alonso-Llamazares, Javier
    Bhatia, Neal
    Bukhalo, Michael
    Devani, Alim R.
    Draelos, Zoe D.
    DuBois, Janet
    Gooderham, Melinda J.
    Kempers, Steven E.
    Lain, Edward
    Lee, Mark
    Moore, Angela
    Murrell, Dedee F.
    Papp, Kim A.
    Pariser, David M.
    Sinclair, Rodney
    Zirwas, Matthew
    Burnett, Patrick
    Higham, Robert C.
    Krupa, David
    Berk, David R.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (04) : 392 - 399
  • [5] A randomized, double-blind, vehicle-controlled phase 2b study of once-daily roflumilast foam 0.3% for scalp and body psoriasis
    Kircik, L. H.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 13 - 13
  • [6] Pimecrolimus cream (1%) efficacy in perioral dermatitis -: results of a randomized, double-blind, vehicle-controlled study in 40 patients
    Oppel, T.
    Pavicic, T.
    Kamann, S.
    Braeutigam, M.
    Wollenberg, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 (09) : 1175 - 1180
  • [7] Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: assessment of pruritus
    Blauvelt, Andrew
    Draelos, Zoe D.
    Gooderham, Melinda
    Lain, Edward
    Moore, Angela Y.
    Papp, Kim A.
    Zirwas, Matthew
    Krupa, David
    Burnett, Patrick
    Berk, David R.
    Chu, David H.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [8] Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: Assessment of Pruritus
    Blauvelt, Andrew
    Draelos, Zoe
    Gooderham, Melinda
    Lain, Edward
    Moore, Angela
    Papp, Kim
    Zirwas, Matthew
    Krupa, David
    Burnett, Patrick
    Berk, David
    Chu, David
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB156 - AB156
  • [9] EFFICACY AND SAFETY OF ROFLUMILAST FOAM 0.3% IN PATIENTS WITH SEBORRHEIC DERMATITIS IN A PHASE 3 TRIAL: ASSESSMENT OF PRURITUS
    Blauvelt, A.
    Draelos, Z. D.
    Gooderham, M.
    Lain, E.
    Moore, A. Y.
    Papp, K. A.
    Zirwas, M.
    Krupa, D.
    Burnett, P.
    Berk, D. R.
    Chu, D. H.
    VALUE IN HEALTH, 2023, 26 (06) : S59 - S59
  • [10] Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis
    Warshaw, Erin M.
    Wohlhuter, Ross Jon
    Liu, An
    Zeller, Sarah A.
    Wenner, Rachel A.
    Bowers, Sacharitha
    Schultz, Julie C.
    Katz, H. Irving
    McCormick, Calogera L.
    Parneix-Spake, Anne
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 57 (02) : 257 - 264
12345